Clinical Trial Update: Study of Irofulven in Patients With Hormone-refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of irofulven in hormone-refractory prostate cancer has been completed. The document provides the trial status and sponsor details.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Irofulven (irofulven)

Snippet

Sponsor: Eisai Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED